The Level of Effectiveness Use of Quinoline Drugs in COVID-19: A Literature Review
Article Sidebar
Vol. 4 No. 2 (2020)
May 31, 2020
July 29, 2020
Abstract
ABSTRACT
         Chloroquine is the first line of medicine in the treatment of malaria. Besides being antimalaria, the chloroquine also can be used as the anti-inflammation in the medicine of arthritis rheumatoid arthritis and lupus erythematosus discoid. Hydroxychloroquine sulfate is 4-aminoquinolin with hydroxylated chloroquine analog, having the same pharmacokinetic as chloroquine which is given orally in hydroxychloroquine sulfate form, processed by gastrointestinal absorption and very faster kidney elimination. The effectiveness of chloroquine and hydroxychloroquine towards COVID-19 in the in vitro experiment showed it could inhibit the duplication of the SARS-CoV-2 virus. The chloroquine function is to stop COVID-19 infection with (EC50) 1,13 μM and (CC50) larger than 100 μM. Meanwhile, the hydroxychloroquine function is to inhibit the attachment and entry of the virus into the host’s cell by enzymatic activation which is the lysosome acidification disorder and antigen presentation as the result of pH increase. Based on the clinical study, the 10 of 12 patients who have lopinavir/ritonavir therapy by virology, the chloroquine group showed RT-PCR negative on day 7, 10, and 14 in compare to lopinavir/ritonavir that showed RT-PCR negative on day 14. On the 9th day, 60% of the patients of chloroquine group showed the CT scan of Lungs image normal instead of the lopinavir/ritonavir at 25%. In the day 14 based on the CT test result, the pulmonary improvement increased twice rather than chloroquine group (Rate Ratio 2.21). It proved that the chloroquine role showed the result of the medicine has a significant effect by cleaning the virus or other clinical matters. The purpose of this literature review is to know the effectiveness quinoline class of drugs which is chloroquine and hydroxychloroquine in COVID-19 disease.
Keywords: effectiveness, chloroquine, COVID-19
Correspondence: dedydermawan555@gmail.com
References
Al-Bari, M. A. A. (2017). Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases. Pharmacology Research and Perspectives, 5(1), 1–13. https://doi.org/10.1002/prp2.293
Barlow, A., Landolf, K. M., Barlow, B., Yeung, S. Y. A., Heavner, J. J., Claassen, C. W., et al. (2020). Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019. Pharmacotherapy, 40(5), 416–437. https://doi.org/10.1002/phar.2398
Cortegiani, A., Ingoglia, G., Ippolito, M., Giarratano, A., & Einav, S. (2020). A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. Journal of Critical Care, 57, 279–283. https://doi.org/10.1016/j.jcrc.2020.03.005
Cai, H. (2020). Sex difference and smoking predisposition in patients with COVID-19. The Lancet Respiratory Medicine, 8(4), e20. https://doi.org/10.1016/S2213-2600(20)30117-X
Devaux, C. A., Rolain, J.-M., Colson, P., & Raoult, D. (2020). New insights on the antiviral effects of chloroquine against Coronavirus: what to expect for COVID-19? International Journal of Antimicrobial Agents, December 2019, 105938. https://doi.org/10.1016/j.ijantimicag.2020.105938
FDA Drug Safety Communication (2020). FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems [Internet]. Available from: https://www.fda.gov/safety/medical-product-safety-information/hydroxychloroquine-or-chloroquine-covid-19-drug-safety-communication-fda-cautions-against-use. (Accessed June 13, 2020)
Ferner, R. E., & Aronson, J. K. (2020). Chloroquine and hydroxychloroquine in covid-19. Bmj, 1432(April), m1432. https://doi.org/10.1136/bmj.m1432
Frater, J. L., Zini, G., d’Onofrio, G., & Rogers, H. J. (2020). COVID-19 and the clinical hematology laboratory. International Journal of Laboratory Hematology, 2, 0–3. https://doi.org/10.1111/ijlh.13229
Gao, J., Tian, Z., & Yang, X. (2020). Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. BioScience Trends, 14(1), 1–2. https://doi.org/10.5582/BST.2020.01047
Goel, P., & Gerriets, V. (2019). Chloroquine. StatPearls [Internet]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK551512/ (Accessed June 16, 2020)
Gautret, P., Lagier, J.-C., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., et al. (2020). Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents, 105949. https://doi.org/10.1016/j.ijantimicag.2020.105949
Han, Y., & Yang, H. (2020). The transmission and diagnosis of 2019 novel coronavirus infection disease (COVID-19): A Chinese perspective. Journal of Medical Virology, March, 639–644. https://doi.org/10.1002/jmv.25749
Hashem, A. M., Alghamdi, B. S., Algaissi, A. A., Alshehri, F. S., Bukhari, A., Alfaleh, M. A., et al. (2020). Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review. Travel Medicine and Infectious Disease, 101735. https://doi.org/10.1016/j.tmaid.2020.101735
Huang, J., Song, W., Huang, H., & Sun, Q. (2020). Pharmacological Therapeutics Targeting RNA-Dependent RNA Polymerase, Proteinase and Spike Protein: From Mechanistic Studies to Clinical Trials for COVID-19. Journal of Clinical Medicine, 9(4), 1131. https://doi.org/10.3390/jcm9041131
Huang, M., Tang, T., Pang, P., Li, M., Ma, R., Lu, J., et al. (2020). Treating COVID-19 with Chloroquine. Journal of Molecular Cell Biology, 12, 322–325. https://doi.org/10.1093/jmcb/mjaa014
Jin, Y., Yang, H., Ji, W., Wu, W., Chen, S., Zhang, W., et al. (2020). Virology, epidemiology, pathogenesis, and control of covid-19. Viruses, 12(4), 1–17. https://doi.org/10.3390/v12040372
Liu, J., Cao, R., Xu, M., Wang, X., Zhang, H., Hu, H., et al. (2020). Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discovery, 6(1), 6–9. https://doi.org/10.1038/s41421-020-0156-0
Preventation CDC (2020). Interim US Guidance for Risk Assessment and Public Health Management of Persons with Potential Coronavirus Disease 2019 (COVID-19) Exposures: in a Healthcare Setting to Patients with Coronavirus Disease 2019 (COVID-19) [Internet]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-risk-assesment-hcp.html.
Ponticelli, C., & Moroni, G. (2017). Hydroxychloroquine in systemic lupus erythematosus (SLE). Expert Opinion on Drug Safety, 16(3), 411–419. https://doi.org/10.1080/14740338.2017.1269168
Pastick, K. A., Okafor, E. C., Wang, F., Lofgren, S. M., Skipper, C. P., Nicol, M. R., et al. (2020). Review: Hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19). Open Forum Infectious Diseases, 7(4), 1–9. https://doi.org/10.1093/ofid/ofaa130
Quiros Roldan, E., Biasiotto, G., Magro, P., & Zanella, I. (2020). The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis? Pharmacological Research, 158(April), 104904. https://doi.org/10.1016/j.phrs.2020.104904
Rothan, H. A., & Byrareddy, S. N. (2020). The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. Journal of Autoimmunity, 109(February), 102433. https://doi.org/10.1016/j.jaut.2020.102433
Sun, P., Lu, X., Xu, C., Sun, W., & Pan, B. (2020). Understanding of COVID-19 based on current evidence. Journal of Medical Virology, 0–1. https://doi.org/10.1002/jmv.25722
Sahraei, Z., Shabani, M., Shokouhi, S., & Saffaei, A. (2020). Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine. International Journal of Antimicrobial Agents, 55(4), 105945. https://doi.org/10.1016/j.ijantimicag.2020.105945
Sinha N, Balayla G. (2020). Hydroxychloroquine and covid-19. Postgrad Med J [Internet]. 2020;1–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32295814
Şimşek Yavuz, S., & Ünal, S. (2020). Antiviral treatment of covid-19. Turkish Journal of Medical Sciences, 50(SI-1), 611–619. https://doi.org/10.3906/sag-2004-145
Singh, A. K., Singh, A., Shaikh, A., Singh, R., & Misra, A. (2020). Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 14(3), 241–246. https://doi.org/10.1016/j.dsx.2020.03.011
Taccone, F. S., Gorham, J., & Vincent, J. L. (2020). Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base. The Lancet Respiratory Medicine, c(20), 3–5. https://doi.org/10.1016/S2213-2600(20)30172-7
Touret, F., & de Lamballerie, X. (2020). Of chloroquine and COVID-19. Antiviral Research, 177(February), 104762. https://doi.org/10.1016/j.antiviral.2020.104762
Vincent, M. J., Bergeron, E., Benjannet, S., Erickson, B. R., Rollin, P. E., Ksiazek, T. G., et al. (2005). Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virology Journal, 2, 1–10. https://doi.org/10.1186/1743-422X-2-69
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., et al. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research, 30(3), 269–271. https://doi.org/10.1038/s41422-020-0282-0
World Health Organization. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV). 2020. At https://www.who.int/news-room/detail/30-01-2020-statement-onthe-second-meeting-of-the-international-health-regulations-(2005)-emergencycommittee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov) . Published January 31, 2020. 9.
World Health Organization. WHO Director-General's remarks at the media briefing on 2019-nCoV on February 11 2020. 2020. at https://www.who.int/dg/speeches/detail/whodirector-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020.Published February 11, 2020. 10.
Yang, J., Zheng, Y., Gou, X., Pu, K., Chen, Z., Guo, Q., et al. (2020). Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. International Journal of Infectious Diseases, 94, 91-95. http://doi.org/10.1016/j.ijid.2020.03.017
Yao, X., Ye, F., Zhang, M., Cui, C., Huang, B., Niu, P., et al. (2020). In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, Xx, 1–8. https://doi.org/10.1093/cid/ciaa23
Zhou, D., Dai, S.-M., & Tong, Q. (2020). COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. Journal of Antimicrobial Chemotherapy, February, 4-7. https://doi.org/10.1093/jac/dkaa114
Zhang, W., Zhao, Y., Zhang, F., Wang, Q., Li, T., Liu, Z., et al. (2020). The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from China. Clinical Immunology, 214(March), 108393. https://doi.org/10.1016/j.clim.2020.108393
Authors
Qanun Medika by FK UM Surabaya is liscence under Lisensi Creative Commons Atribusi 4.0 Internasional.
